Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
ID07510438

AVS Pulse Intravascular Lithotripsy (Pulse IVL) to Open Vessels With Calcific Walls and Enhance Vascular Compliance and Remodeling for Coronary Artery Disease - A First-in-Human Study

Led by Amplitude Vascular Systems, Inc. · Updated on 2026-05-18

15

Participants Needed

2

Research Sites

52 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are evaluating the safety and early effectiveness of the AVS Pulse Intravascular Lithotripsy (Pulse IVL) System for treating coronary artery disease. This first-in-human, open-label study will include up to fifteen patients with severely calcified coronary arteries. The study aims to assess how well the device opens vessels with calcific walls and enhances vascular compliance and remodeling. Participants will receive treatment using the Pulse IVL System to prepare severely calcified coronary arteries before stenting. The study focuses on treating single new coronary lesions in arteries such as the left anterior descending, right coronary, left circumflex, or ramus intermedius. The treatment involves using the device to break down calcifications to allow stent placement. This study has no placebo or comparator group, and all participants receive the investigational device. During the study, participants will be closely monitored for residual narrowing of the artery after treatment and stenting, aiming for less than 50% stenosis. Researchers will also track any major device-related adverse events and target lesion failure within 30 days of the procedure. Participants will undergo assessments including imaging and clinical evaluations to measure safety and effectiveness. The study is expected to continue through December 2027, with detailed follow-up after the procedure.

CONDITIONS

Brief Title

AVS Pulse Intravascular Lithotripsy™ (Pulse IVL™) to Open Vessels With Calcific Walls and Enhance Vascular Compliance and Remodeling for Coronary Artery Disease

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • 18 years of age or older
  • Diagnosis of native coronary artery disease
  • Left ventricular ejection fraction (LVEF) of 35% or higher within the last 6 months
  • Single de novo coronary artery lesion
  • Target lesion stenosis of 70% or more and less than 100%, or stenosis 50% or more and less than 70% with evidence of ischemia
  • Lesion length not exceeding 44 mm
Not Eligible

You will not qualify if you...

  • Acute myocardial infarction (STEMI or NSTEMI) within 30 days prior to procedure
  • New York Heart Association (NYHA) class III or IV heart failure
  • Renal failure with serum creatinine greater than 2.5 mg/dL or on chronic dialysis
  • Previous stent in the target vessel within last 6 months
  • Unprotected left main coronary artery (LMCA) diameter stenosis greater than 30%
  • Target lesion with myocardial bridge
  • Target vessel excessively tortuous with 2 or more bends over 90 degrees or 3 or more bends over 75 degrees
  • Evidence of aneurysm near the target lesion
  • Target lesion in ostial location or unprotected LMCA
  • Target lesion is a bifurcation with ostial diameter stenosis 30% or more
  • Any previous stent within 10 mm of target lesion

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

Implementation

Duration - Single procedure day

Participants undergo the Pulse Intravascular Lithotripsy (Pulse IVL) procedure to open vessels with calcific walls prior to stenting for coronary artery disease.

1 in-person procedure visit

Trial Site Locations

Total: 2 locations

1

Monash Health, Victorian Heart Hospital

Melbourne, Victoria, Australia, 3168

Actively Recruiting

2

Auckland City Hospital

Auckland, New Zealand, 1142

Actively Recruiting

Loading map...

Research Team

E

Elizabeth Galle

E

Elise Gendreau

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Similar Trials

AGENT DCB STANCE: AGENT Drug-Coated Balloon for STent AvoidA...

Coronary Arterial Disease (CAD)

Actively Recruiting

55 locations

Artificial Intelligence Based Timing, Infarct Size and Outco...

Coronary Arterial Disease (CAD)

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here